[ Case study 02 ] Biodefense
Elusys Therapeutics
The anthrax antitoxin licensed as a medical countermeasure in the United States and Canada.
- Focus area
- Biodefense
- Leadership
- Jeff Wolf, Chairman and CEO
- Product
- ANTHIM (obiltoxaximab)
- Outcome
- Licensed in the US and Canada
The company
Elusys Therapeutics uses immune-stimulatory and immune-derived therapies to combat infectious disease.
Its anthrax antitoxin, obiltoxaximab, is licensed as ANTHIM® in the United States and Canada. It is a medical countermeasure that mitigates the effect of anthrax exposure after a natural incident or an intentional attack.
The company's mission is to accelerate the development and commercialization of novel biodefense solutions: to defend tomorrow, today.
Seed One's roleSeed One Managing Partner Jeff Wolf serves as Elusys' Chairman and CEO.
Licensed in
As a medical countermeasure.
Antitoxin
Obiltoxaximab, for anthrax exposure.
[ Contact ] Have a breakthrough?
Elusys started as a breakthrough in a lab. If you have technology that could reshape an industry, we want to hear from you.